Study backs preventive use of long-acting CCBs

Cardiovascular - Long-acting calcium-channel blockers did not cause excess cardiovascular adverse effects.

Long-acting calcium-channel blockers (CCBs) can cut cardiovascular events in patients with coronary artery disease, a meta-analysis has shown.

This finding runs contrary to previous suggestions that these medications increase the risk of MI and all-cause mortality in patients who have coronary artery disease.

Short-acting CCBs have been thought to be an unfavourable pharmacological treatment option for patients with coronary artery disease or hypertension.

However, these concerns have been extended to long- acting CCBs despite their effect on patients with coronary artery disease being poorly defined, US researchers said.

The researchers looked at 15 randomised controlled trials of long-acting CCBs in patients with coronary artery disease conducted between 1966 and 2008.

They found that there was a 28 per cent reduction in heart failure, 21 per cent reduction in stroke and 18 per cent reduction in angina pectoris in patients with coronary artery disease who had taken long-acting CCBs.

The researchers from the Columbia University College of Physicians and Surgeons said: 'Long-acting CCBs were not associated with any excess cardiovascular events and were associated with a reduction in the risk of stroke, angina pectoris and heart failure compared with the comparison group.'

They added: 'Long-acting CCBs should therefore be considered in the armamentarium of treatment for patients with coronary artery disease.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in